Trials (Gustave Roussy) - Revision history

Francine at 19:11, 14 December 2025

2025-12-14T19:11:01Z

← Older revision		Revision as of 19:11, 14 December 2025
Line 4:		Line 4:
	<span style="display:none">francecountry</span>		<span style="display:none">francecountry</span>
	Go back to [[Gustave Roussy]] page		Go back to [[Gustave Roussy]] page

			=== Trials: How to participate ===
			'''Contact information:''' [https://www.gustaveroussy.fr/fr/recherche-clinique Click here to access].


	'''NCTID''': NCT02666690		'''NCTID''': NCT02666690
Line 8,441:		Line 8,445:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:41:12Z

Update categories.

← Older revision		Revision as of 12:41, 6 December 2025
Line 8,420:		Line 8,420:
	<span style="display:none">hasTrialTitle::A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)</span>		<span style="display:none">hasTrialTitle::A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)</span>
	<span style="display:none">hasTrialTitle::Adjuvant Pazopanib in Stage I NSCLC</span>		<span style="display:none">hasTrialTitle::Adjuvant Pazopanib in Stage I NSCLC</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 11:56, 3 December 2025

2025-12-03T11:56:14Z

← Older revision		Revision as of 11:56, 3 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
			<span style="display:none">francecountry</span>
	Go back to [[Gustave Roussy]] page		Go back to [[Gustave Roussy]] page

Lucas: Update categories.

2025-12-02T13:58:55Z

Update categories.

@@ Line 1: / Line 1: @@
-{{forpatients}}
+<span style="display:none">forpatients</span>
-{{forproviders}}
+<span style="display:none">forproviders</span>
-{{forresearchers}}
+<span style="display:none">forresearchers</span>
 Go back to [[Gustave Roussy]] page
@@ Line 8,379: / Line 8,379: @@
   '''Recruitment Status''': RECRUITING
   '''Condition''': Advanced, Pretreated Solid Tumors

Francine at 13:47, 5 January 2024

2024-01-05T13:47:53Z

← Older revision		Revision as of 13:47, 5 January 2024
Line 315:		Line 315:
	'''Condition''': Oligometastatic Hormone Sensitive Prostate Cancer		'''Condition''': Oligometastatic Hormone Sensitive Prostate Cancer
	'''NCTID''': NCT03635983		'''NCTID''': NCT03635983
	'''Title''': A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma		'''Title''': [[hasTrialTitle::A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma]]
	'''Study Summary''': The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread		'''Study Summary''': The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
	'''Sponsor''': Bristol-Myers Squibb		'''Sponsor''': Bristol-Myers Squibb
Line 325:		Line 325:
	'''Condition''': Melanoma		'''Condition''': Melanoma
	'''NCTID''': NCT03138083		'''NCTID''': NCT03138083
	'''Title''': OMO-1 in Solid Malignancies		'''Title''': [[hasTrialTitle::OMO-1 in Solid Malignancies]]
	'''Study Summary''': This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.		'''Study Summary''': This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.
	'''Sponsor''': Octimet Oncology N.V.		'''Sponsor''': Octimet Oncology N.V.
Line 335:		Line 335:
	'''Condition''': Neoplasms		'''Condition''': Neoplasms
	'''NCTID''': NCT02298283		'''NCTID''': NCT02298283
	'''Title''': Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD		'''Title''': [[hasTrialTitle::Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD]]
	'''Study Summary''': This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).		'''Study Summary''': This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).
	'''Sponsor''': The Lymphoma Academic Research Organisation		'''Sponsor''': The Lymphoma Academic Research Organisation
Line 345:		Line 345:
	'''Condition''': Hodgkin Lymphoma		'''Condition''': Hodgkin Lymphoma
	'''NCTID''': NCT03964233		'''NCTID''': NCT03964233
	'''Title''': A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111		'''Title''': [[hasTrialTitle::A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111]]
	'''Study Summary''': This study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumors). The second part is open to people with specific types of soft tissue sarcoma, advanced lung cancer, and cancer in the stomach, bladder or bile ducts. The participants get a combination of 2 medicines called BI 907828 and ezabenlimab (also called BI 754091). BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor). When the study started, some participants got a third medicine called BI 754111 in addition. Treatment with BI 754111 was stopped because data from another study showed no additional effect of BI 754111. The purpose of the first part of the study is to find out the highest dose of BI 907828 that the participants can tolerate in combination with ezabenlimab. Once the best dose of BI 907828 for the combination with ezabenlimab is found, it will be used in the second part of the study. The purpose of the second part is to see whether the combination of BI 907828 with ezabenlimab is able to make tumors shrink. The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of ezabenlimab, and take tablets with BI 907828 every 3 weeks. The doctors check how many participants have health problems during the study. The doctors also monitor the size of the tumour.		'''Study Summary''': This study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumors). The second part is open to people with specific types of soft tissue sarcoma, advanced lung cancer, and cancer in the stomach, bladder or bile ducts. The participants get a combination of 2 medicines called BI 907828 and ezabenlimab (also called BI 754091). BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor). When the study started, some participants got a third medicine called BI 754111 in addition. Treatment with BI 754111 was stopped because data from another study showed no additional effect of BI 754111. The purpose of the first part of the study is to find out the highest dose of BI 907828 that the participants can tolerate in combination with ezabenlimab. Once the best dose of BI 907828 for the combination with ezabenlimab is found, it will be used in the second part of the study. The purpose of the second part is to see whether the combination of BI 907828 with ezabenlimab is able to make tumors shrink. The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of ezabenlimab, and take tablets with BI 907828 every 3 weeks. The doctors check how many participants have health problems during the study. The doctors also monitor the size of the tumour.
	'''Sponsor''': Boehringer Ingelheim		'''Sponsor''': Boehringer Ingelheim
Line 355:		Line 355:
	'''Condition''': Neoplasms		'''Condition''': Neoplasms
	'''NCTID''': NCT03472807		'''NCTID''': NCT03472807
	'''Title''': EXOme Rare Cancers in Children (EXOCARE)		'''Title''': [[hasTrialTitle::EXOme Rare Cancers in Children (EXOCARE)]]
	'''Study Summary''': Other than high-dose radiation and previous chemotherapy, few strong risk factors have been identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers diagnosed during the paediatric period occur in children born with a genetic mutation, increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with congenital anomalies and specific genetic syndromes. Some germline genetic alterations are well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children with none of these mutations have clinical presentations that strongly suggest the involvement of a genetic predisposition. Comprehensive genetic testing for all such patients is an important factor for improving disease surveillance. Such opportunities are now available thanks to whole exome sequencing (WES). In oncology, an important clinical application of WES will be to routinely identify mutations associated with inherited cancer predispositions and to guide cancer risk-management decisions. Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours. The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.		'''Study Summary''': Other than high-dose radiation and previous chemotherapy, few strong risk factors have been identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers diagnosed during the paediatric period occur in children born with a genetic mutation, increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with congenital anomalies and specific genetic syndromes. Some germline genetic alterations are well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children with none of these mutations have clinical presentations that strongly suggest the involvement of a genetic predisposition. Comprehensive genetic testing for all such patients is an important factor for improving disease surveillance. Such opportunities are now available thanks to whole exome sequencing (WES). In oncology, an important clinical application of WES will be to routinely identify mutations associated with inherited cancer predispositions and to guide cancer risk-management decisions. Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours. The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.
	'''Sponsor''': University Hospital, Angers		'''Sponsor''': University Hospital, Angers
Line 365:		Line 365:
	'''Condition''': Predisposition, Genetic		'''Condition''': Predisposition, Genetic
	'''NCTID''': NCT02467907		'''NCTID''': NCT02467907
	'''Title''': Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer		'''Title''': [[hasTrialTitle::Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer]]
	'''Study Summary''': This study is to assess safety as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants treated with bevacizumab 15 milligrams per kilogram (mg/kg) in combination with paclitaxel and carboplatin, all repeated every 3 weeks, for recurrent, persistent or metastatic cervical cancer. In addition, this study will include evaluation of the overall safety profile of bevacizumab in combination with paclitaxel and carboplatin in this setting, assessment of GI perforation/fistula, GI-vaginal fistula and GU fistula events over time, and evaluation of efficacy.		'''Study Summary''': This study is to assess safety as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants treated with bevacizumab 15 milligrams per kilogram (mg/kg) in combination with paclitaxel and carboplatin, all repeated every 3 weeks, for recurrent, persistent or metastatic cervical cancer. In addition, this study will include evaluation of the overall safety profile of bevacizumab in combination with paclitaxel and carboplatin in this setting, assessment of GI perforation/fistula, GI-vaginal fistula and GU fistula events over time, and evaluation of efficacy.
	'''Sponsor''': Hoffmann-La Roche		'''Sponsor''': Hoffmann-La Roche
Line 375:		Line 375:
	'''Condition''': Cervical Cancer		'''Condition''': Cervical Cancer
	'''NCTID''': NCT05742607		'''NCTID''': NCT05742607
	'''Title''': IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)		'''Title''': [[hasTrialTitle::IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)]]
	'''Study Summary''': The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).		'''Study Summary''': The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
	'''Sponsor''': Innate Pharma		'''Sponsor''': Innate Pharma
Line 385:		Line 385:
	'''Condition''': Non Small Cell Lung Cancer		'''Condition''': Non Small Cell Lung Cancer
	'''NCTID''': NCT04817007		'''NCTID''': NCT04817007
	'''Title''': A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)		'''Title''': [[hasTrialTitle::A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)]]
	'''Study Summary''': The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.		'''Study Summary''': The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.
	'''Sponsor''': Bristol-Myers Squibb		'''Sponsor''': Bristol-Myers Squibb
Line 395:		Line 395:
	'''Condition''': Myelofibrosis		'''Condition''': Myelofibrosis
	'''NCTID''': NCT00775307		'''NCTID''': NCT00775307
	'''Title''': Adjuvant Pazopanib in Stage I NSCLC		'''Title''': [[hasTrialTitle::Adjuvant Pazopanib in Stage I NSCLC]]
	'''Study Summary''': The aim of this study is to evaluate the efficacy and safety of pazopanib compared with placebo in patients with T < or = 5 cm, N0 (stage I according to TNM 2009) completely resected NSCLC.		'''Study Summary''': The aim of this study is to evaluate the efficacy and safety of pazopanib compared with placebo in patients with T < or = 5 cm, N0 (stage I according to TNM 2009) completely resected NSCLC.
	'''Sponsor''': Intergroupe Francophone de Cancerologie Thoracique		'''Sponsor''': Intergroupe Francophone de Cancerologie Thoracique

Francine at 13:37, 5 January 2024

2024-01-05T13:37:38Z

Show changes

Francine at 13:27, 5 January 2024

2024-01-05T13:27:12Z

Show changes

Francine at 12:19, 4 December 2023

2023-12-04T12:19:40Z

Show changes

Francine: Created page with "'''[https://www.gustaveroussy.fr/en/essais-cliniques Ongoing Clinical Trials]'''"

2023-11-07T12:58:41Z

Created page with "'''[https://www.gustaveroussy.fr/en/essais-cliniques Ongoing Clinical Trials]'''"

New page

'''[https://www.gustaveroussy.fr/en/essais-cliniques Ongoing Clinical Trials]'''